Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312970 · ClinicalTrials.gov registry record · Phase 4
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
A Phase 4 study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT05312970 is a Phase 4 study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 43 participants.
The verdict
NCT05312970, a Phase 4 study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
Interventions
- DRUG Varithena®
- DEVICE FDA-approved Endothermal Ablation (ETA) systems
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05312970
The ClinicalTrials.gov registry entry for NCT05312970 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Varithena® is the first listed.
NCT05312970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05312970 about?
NCT05312970 is a clinical study titled "Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)". The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
What is the current status of trial NCT05312970?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2023-02-10. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT05312970?
The interventions under investigation include: Varithena® (DRUG), FDA-approved Endothermal Ablation (ETA) systems (DEVICE).
Who is sponsoring clinical trial NCT05312970?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.